Excerpt taken from the full Press Release: PRNewswire, August 11, 2021.
1 in 3 people will be diagnosed with cancer in their lifetime1
LAKEWOOD, Colo. and FORT COLLINS, Colo., Aug. 11, 2021 /PRNewswire/ —Terumo Blood and Cell Technologies (Terumo), a medical device company specializing in a portfolio of technology, software and services for blood component collection, therapeutic apheresis and cellular technologies, and PhotonPharma Inc., a cancer immunotherapy developer, today announced they have established a memorandum of understanding (MOU) for collaboration to develop Innocell™, a novel tumor specific immunotherapy (a therapeutic vaccine) for solid tumors. The benefit to patients is that collaborations like this can help improve the speed to market for valuable treatments.
This MOU is the first part of a longer-term collaboration to advance PhotonPharma’s Innocell. The collaboration focuses on the development, regulatory approval and future commercialization of PhotonPharma’s Innocell vaccine. PhotonPharma is currently preparing an Investigational New Drug (IND) submission related to a phase I clinical trial targeting triple-negative breast cancer.
“This agreement to work together with Terumo increases the potential to advance a new therapy for patients suffering from a variety of solid tumor malignancies including breast cancer,” said Dr. Gary Gordon, M.D., Ph.D., former Divisional Vice President of Abbvie Oncology and PhotonPharma board member. “Working together will benefit patients in need of new therapeutic approaches to treat their underlying disease.”